News coverage about Alexion Pharmaceuticals (NASDAQ:ALXN) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.6130481471341 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the media stories that may have effected Accern’s scoring:

Shares of Alexion Pharmaceuticals (ALXN) traded up $0.54 during mid-day trading on Monday, hitting $118.78. The stock had a trading volume of 973,931 shares, compared to its average volume of 2,288,024. The company has a market cap of $26,415.95, a price-to-earnings ratio of 53.03, a P/E/G ratio of 1.29 and a beta of 1.18. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. During the same period in the previous year, the company posted $1.23 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. research analysts forecast that Alexion Pharmaceuticals will post 4.82 EPS for the current fiscal year.

A number of equities research analysts recently commented on ALXN shares. TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target on the stock in a research report on Tuesday, October 31st. Royal Bank of Canada started coverage on Alexion Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $161.00 price target on the stock. Credit Suisse Group restated a “buy” rating and set a $166.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. Finally, Stifel Nicolaus reduced their price target on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average price target of $155.70.

TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals (ALXN) Given Daily Coverage Optimism Score of 0.22” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2017/12/25/alexion-pharmaceuticals-alxn-given-daily-coverage-optimism-score-of-0-22.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.